Henri Theunissen
Amministratore Delegato presso BioMedbooster BV
Profilo
Dr. Henri Theunissen is a Managing Director at BioMedBooster BV and a Chief Executive Officer at Simmunext Biotherapeutics BV.
Dr. Theunissen was previously employed as a Director-Supervisory Board by ACS Biomarker BV, a Vice President by Diosynth RTP, Inc., a Principal by Nobilon International BV, and a Principal by Organon International BV.
He received his undergraduate degree from Radboud University Nijmegen and a doctorate degree from the University of Amsterdam.
Posizioni attive di Henri Theunissen
Società | Posizione | Inizio |
---|---|---|
BioMedbooster BV
BioMedbooster BV Miscellaneous Commercial ServicesCommercial Services BioMedbooster BV provides valorization services. It supports businesses in translating their inventions or ideas into products ready for marketing. The company builds bridges between scientific research and industry, especially in life sciences and biomedical technologies. The firm offers evaluation of commercial potential of the invention, market analysis, managing the patenting process, business plan development, financial support for patent application in selected cases, business development financing, finding seed capital, monitoring contracts and payments, strong connections in scientific, industrial and financial communities, finding licensees and monitoring patent infringement. BioMedbooster was founded in 2005 and is headquartered in Maastricht, the Netherlands. | Amministratore Delegato | 01/11/2009 |
Precedenti posizioni note di Henri Theunissen
Società | Posizione | Fine |
---|---|---|
ACS Biomarker BV
ACS Biomarker BV Medical SpecialtiesHealth Technology ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands. | Direttore/Membro del Consiglio | - |
Diosynth RTP, Inc.
Diosynth RTP, Inc. BiotechnologyHealth Technology Diosynth RTP, Inc. provides current good manufacturing practices and pharmaceutical products. Its products include monoclonal antibodies, cancer vaccines, fusion proteins, cancer vaccines, and anti coagulants. The company was founded on February 28, 1995 and is headquartered in Morrisville, NC | Corporate Officer/Principal | - |
Nobilon International BV | Corporate Officer/Principal | - |
Organon International BV | Corporate Officer/Principal | - |
Formazione di Henri Theunissen
Radboud University Nijmegen | Undergraduate Degree |
University of Amsterdam | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
BioMedbooster BV
BioMedbooster BV Miscellaneous Commercial ServicesCommercial Services BioMedbooster BV provides valorization services. It supports businesses in translating their inventions or ideas into products ready for marketing. The company builds bridges between scientific research and industry, especially in life sciences and biomedical technologies. The firm offers evaluation of commercial potential of the invention, market analysis, managing the patenting process, business plan development, financial support for patent application in selected cases, business development financing, finding seed capital, monitoring contracts and payments, strong connections in scientific, industrial and financial communities, finding licensees and monitoring patent infringement. BioMedbooster was founded in 2005 and is headquartered in Maastricht, the Netherlands. | Commercial Services |
Organon International BV | |
Diosynth RTP, Inc.
Diosynth RTP, Inc. BiotechnologyHealth Technology Diosynth RTP, Inc. provides current good manufacturing practices and pharmaceutical products. Its products include monoclonal antibodies, cancer vaccines, fusion proteins, cancer vaccines, and anti coagulants. The company was founded on February 28, 1995 and is headquartered in Morrisville, NC | Health Technology |
Nobilon International BV | |
ACS Biomarker BV
ACS Biomarker BV Medical SpecialtiesHealth Technology ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Henri Theunissen